These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14567634)

  • 21. A quantitative structure-activity relationship (QSAR) study of dermal absorption using theoretical molecular descriptors.
    Basak SC; Mills D; Mumtaz MM
    SAR QSAR Environ Res; 2007; 18(1-2):45-55. PubMed ID: 17365958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QSAR modeling of in vitro inhibition of cytochrome P450 3A4.
    Mao B; Gozalbes R; Barbosa F; Migeon J; Merrick S; Kamm K; Wong E; Costales C; Shi W; Wu C; Froloff N
    J Chem Inf Model; 2006; 46(5):2125-34. PubMed ID: 16995743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4).
    Chougnet A; Stoessel C; Woggon WD
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3643-5. PubMed ID: 14552748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of small-molecule binding to cytochrome P450 3A4: flexible docking combined with multidimensional QSAR.
    Lill MA; Dobler M; Vedani A
    ChemMedChem; 2006 Jan; 1(1):73-81. PubMed ID: 16892339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. pK(a) modelling and prediction of drug molecules through GA-KPLS and L-M ANN.
    Noorizadeh H; Farmany A; Noorizadeh M
    Drug Test Anal; 2013 Feb; 5(2):103-9. PubMed ID: 21500371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The computational model to predict accurately inhibitory activity for inhibitors towards CYP3A4.
    Xie Z; Zhang T; Wang JF; Chou KC; Wei DQ
    Comput Biol Med; 2010; 40(11-12):845-52. PubMed ID: 20951982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational models for predicting interactions with cytochrome p450 enzyme.
    Arimoto R
    Curr Top Med Chem; 2006; 6(15):1609-18. PubMed ID: 16918472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiomers: Inhibition of cytochrome P450 activity.
    Iqbal J; Sakloetsakun D; Bernkop-Schnürch A
    Eur J Pharm Biopharm; 2011 Aug; 78(3):361-5. PubMed ID: 21362475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QSAR Modeling and Prediction of Drug-Drug Interactions.
    Zakharov AV; Varlamova EV; Lagunin AA; Dmitriev AV; Muratov EN; Fourches D; Kuz'min VE; Poroikov VV; Tropsha A; Nicklaus MC
    Mol Pharm; 2016 Feb; 13(2):545-56. PubMed ID: 26669717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
    Isin EM; Guengerich FP
    J Biol Chem; 2007 Mar; 282(9):6863-74. PubMed ID: 17200113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.
    Ekins S; Bravi G; Wikel JH; Wrighton SA
    J Pharmacol Exp Ther; 1999 Oct; 291(1):424-33. PubMed ID: 10490933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors.
    Roy K; Roy PP
    Chem Biol Drug Des; 2008 Nov; 72(5):370-82. PubMed ID: 19012573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis.
    Korhonen LE; Turpeinen M; Rahnasto M; Wittekindt C; Poso A; Pelkonen O; Raunio H; Juvonen RO
    Br J Pharmacol; 2007 Apr; 150(7):932-42. PubMed ID: 17325652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of genetic algorithm-kernel partial least square as a novel non-linear feature selection method: partitioning of drug molecules.
    Noorizadeh H; Sobhan Ardakani S; Ahmadi T; Mortazavi SS; Noorizadeh M
    Drug Test Anal; 2013 Feb; 5(2):89-95. PubMed ID: 21438162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods.
    Hudelson MG; Ketkar NS; Holder LB; Carlson TJ; Peng CC; Waldher BJ; Jones JP
    J Med Chem; 2008 Feb; 51(3):648-54. PubMed ID: 18211009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QSAR modeling for quinoxaline derivatives using genetic algorithm and simulated annealing based feature selection.
    Ghosh P; Bagchi MC
    Curr Med Chem; 2009; 16(30):4032-48. PubMed ID: 19747124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.